planned spinoff Sandoz and Purdue Pharma subsidiary Rhodes Pharmaceuticals, which all manufacture drugs targeting ADHD, don't need to publicly share information about where they manufacture medications, how much of them they make, where ingredients are sourced and their overall production capacities.
"We don't have the quota amount that each company is given. And we also don't have the amount that each company is actually producing and if they're meeting those quotas," said Fox of the University of Utah."There's no way to understand which company maybe isn't doing the job and which companies are, so we just don't know exactly what's going on.
And even if the DEA does approve a quote change, it could take months to do so:"It's not just flipping a switch and boosting your output by 20%," ASHP's Ganio said.Members of the Drug Enforcement Administration raided two homes side-by-side, in an assumed illegal marijuana operation, on January 31, 2019 in Commerce City, Colorado.
The agencies said an internal analysis found that drugmakers fell 30% short of meeting the full quota for amphetamine medications in 2022, leaving about 1 billion potential drug doses on the table. They added that there's a"similar trend" occurring this year.